Quantbot Technologies LP Buys Shares of 54,441 DaVita Inc. (NYSE:DVA)

Quantbot Technologies LP bought a new stake in DaVita Inc. (NYSE:DVA) during the 3rd quarter, Holdings Channel reports. The fund bought 54,441 shares of the company’s stock, valued at approximately $8,925,000.

Several other institutional investors also recently modified their holdings of DVA. Harvard Management Co. Inc. acquired a new stake in shares of DaVita during the second quarter worth $55,115,000. KBC Group NV boosted its holdings in DaVita by 27.3% during the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after buying an additional 67,250 shares during the last quarter. Andra AP fonden grew its position in shares of DaVita by 9.0% during the 2nd quarter. Andra AP fonden now owns 192,300 shares of the company’s stock worth $26,647,000 after buying an additional 15,800 shares during the period. abrdn plc boosted its stake in DaVita by 1.2% during the 3rd quarter. abrdn plc now owns 189,065 shares of the company’s stock worth $30,719,000 after acquiring an additional 2,180 shares during the last quarter. Finally, FMR LLC increased its stake in DaVita by 659.9% in the third quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after purchasing an additional 154,061 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Activity at DaVita

In other news, CEO Javier Rodriguez sold 50,000 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at $138,284,666.75. This represents a 5.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 2.00% of the stock is owned by insiders.

DaVita Stock Up 0.9 %

DVA stock opened at $166.99 on Tuesday. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. The stock has a market capitalization of $13.69 billion, a P/E ratio of 18.01, a P/E/G ratio of 0.93 and a beta of 0.89. DaVita Inc. has a fifty-two week low of $98.26 and a fifty-two week high of $169.12. The business has a 50-day moving average of $158.34 and a 200-day moving average of $148.65.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The firm had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same period last year, the company earned $2.85 EPS. The company’s revenue was up 4.6% compared to the same quarter last year. On average, sell-side analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Barclays boosted their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. UBS Group raised their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America boosted their price objective on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Finally, Truist Financial raised their target price on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, DaVita presently has an average rating of “Hold” and an average price target of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.